title: Targeting phosphatidylcholine-specific phospholipase C for atherogenesis therapy.
abstract: Atherosclerosis, a dynamic and progressive vascular disease arising from the combination of endothelial dysfunction and inflammation, is becoming a major killer in the 21st century. Accumulating evidence implicates phosphatidylcholine-specific phospholipase C (PC-PLC) in endothelial dysfunction and several inflammation processes. In addition, in a recent study, we demonstrated that PC-PLC contributed to the progression of atherosclerosis. Considering the important roles of PC-PLC in vascular endothelial cell dysfunction and its proinflammatory properties, we propose that a pharmacological blockade of PC-PLC represents a rational approach to atherosclerosis therapy.
authors: Shandong Provincial Key Laboratory of Animal Cells and Developmental Biology, Institute of Developmental Biology, School of Life Science, Shandong University, Jinan 250100, China.
authors: HaiYing
authors: H
authors: Li
authors: Lu
authors: L
authors: Zhang
authors: DeLing
authors: D
authors: Yin
authors: Yun
authors: Y
authors: Zhang
authors: JunYing
authors: J
authors: Miao
mesh_terms: D050197:Atherosclerosis / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D058990:Molecular Targeted Therapy; D010738:Type C Phospholipases / Q000037:antagonists & inhibitors*
chemical_list: D010738:Type C Phospholipases; C105598:phosphatidylcholine-specific phospholipase C